ADPT vs GILD · rev $142.4M vs P/E 18, rev $7.80B
Adaptive Biotechnologies Corp (ADPT) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Adaptive Biotechnologies Corp (ADPT) is a diagnostics & research company listed on NASDAQ.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US. It is led by Daniel P. O'Day.
Latest reported ADPT revenue for 2026-06-30 was $142.4M. Net income was -$59.8M. ADPT currently screens at market cap $2.69B.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
ADPT currently screens at market cap $2.69B. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the ADPT and GILD stock pages for the full models.
Not investment advice.